A study by DJ Graham et al. compared the risks of stroke, bleeding, and mortality in elderly Medicare beneficiaries with nonvalvular atrial fibrillation treated with dabigatran or rivaroxaban. The study included over 118,000 patients and found that dabigatran was associated with a lower risk of majo

0 views • 9 slides

The ATLAS-ACS 2 study investigated the efficacy and safety of rivaroxaban in ACS patients post-index event. The primary endpoints included cardiovascular death, MI, and stroke, with significant reductions seen with rivaroxaban compared to placebo. Stent thrombosis was also reduced with rivaroxaban t

0 views • 10 slides

Explore the world of anticoagulants through images, covering different types like warfarin and NOACs, their indications such as AF, DVT, and PE, monitoring in clinics, and specific drug details like apixaban, rivaroxaban, dabigatran, and edoxaban. Get insights into dosages, administration, and drug

0 views • 27 slides

This study aims to characterize the plasma levels of Dabigatran, Rivaroxaban, and Apixaban in patients with non-valvular atrial fibrillation (NVAF) who have been taking these drugs for more than 4 days. The research also assesses median trough plasma levels of these anticoagulants, as well as their

0 views • 18 slides